

(FILE 'HOME' ENTERED AT 11:24:24 ON 14 DEC 2002)

FILE 'BIOSIS, MEDLINE, INPADOC, CAPLUS' ENTERED AT 11:24:34 ON 14 DEC 2002

L1 38845 (SEPSIS OR SHOCK) AND IMMUNO?
L2 265 L1 AND IMMUNOREGULAT?
L3 156 DUPLICATE REMOVE L2 (109 DUPLICATES REMOVED)
L4 2418 (TREAT? (5A) (SEPSIS OR SHOCK)) AND IMMUNO?
L5 279 L4 AND IMMUNOSUPPRESS?
L6 224 DUPLICATE REMOVE L5 (55 DUPLICATES REMOVED)

=>

QR180.E8

L6 ANSWER 154 OF 224 CAPLUS COPYRIGHT 2002 ACS
AN 1993:641074 CAPLUS
DN 119:241074
TI Linomide, a novel **immunomodulator** that prevents death in four
models of septic shock
AU Gonzalo, Jose ANGel; Gonzalez-Garcia, Ana; Kalland, Terje; Hedlund,
Gunnar; Martinez-A., Carlos; Kroemer, Guido
CS Cent. BIol. Mol., Univ. Auton., Madrid, E-28049, Spain
SO European Journal of Immunology (1993), 23(9), 2372-4
CODEN: EJIMAF; ISSN: 0014-2980
DT Journal
LA English
AB I.v. injections of 50 .mu.g Staphylococcus aureus enterotoxin B (SEB) or
bacterial lipopolysaccharides (LPS) are lethal, provided that mice are
simultaneously sensitized with either N-galactosamine (GalN) or the
anti-glucocorticoid RU-38486. Similar to the synthetic glucocorticoid
(GC) receptor agonist dexamethasone, pharmacol. doses of the
immunomodulator linomide (quinoline-3-carboxamide) prevent death
in all 4 models of lethal septic shock (LPS + GalN, LPS + Ru-38486, SEB +
GalN, and SEB + RU-38486) and inhibit the secretion of tumor necrosis
factor, one of the major intermediate effector mols. of SEB and LPS
toxicity. In this system, cyclosporine A (CsA), although effective in
suppressing SEB toxicity, fails to counteract the lethal effect of LPS.
This observation, together with the fact that linomide acts in the
presence of excess amts. of GC receptor antagonist, indicates that
linomide functions in a different way to that of known
immunosuppressive agents like CsA and GC.

L6 ANSWER 174 OF 224 CAPLUS COPYRIGHT 2002 ACS

AN 1991:527006 CAPLUS

DN 115:127006

TI Biologically active polypeptides based on transforming growth factor-.beta. (TGF-.beta.) sequences, and their use as **immunosuppressive** agents and antiinflammatory agents

IN Burnier, John A.; Cianciolo, George J.

PA Genentech, Inc., USA

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9014359	A1	19901129	WO 1990-US1826	19900404
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	US 5061786	A	19911029	US 1989-356964	19890525
	CA 2057896	AA	19901126	CA 1990-2057896	19900404
	EP 473649	A1	19920311	EP 1990-908073	19900404
	EP 473649	B1	19950201		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	ES 2070322	T3	19950601	ES 1990-908073	19900404
	US 5118791	A	19920602	US 1991-714462	19910613
	US 5268455	A	19931207	US 1992-824622	19920123
PRAI	US 1989-356964		19890525		
	WO 1990-US1826		19900404		
	US 1991-714462		19910613		

OS MARPAT 115:127006

AB The title polypeptides exclude (a) a full-length mature TGF-.beta. mol. or precursor TGF-.beta. mol. or deletion variants of mature or precursor TGF-.beta. mols. in which from about 1 to 10 amino acid residues have been deleted, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) polypeptide of the sequence: Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Leu, said polypeptides comprising amino acid sequences that are based on conserved sequences in the family of TGF-.beta. mols. Such polypeptides are particularly useful therapeutically as **immunosuppressive** agents when coupled to carrier proteins or crosslinked to form polymers. Thus, an albumin conjugate of a peptide of the invention inhibited proliferation of cultured mink lung cells, stimulated PGE2 prodn. from fibroblasts, blocked binding of radiolabeled TGF-.beta. to its receptor, inhibited proliferation of human lymphocytes in response to tetanus toxoid or other species, and inhibited human monocyte chemotactic response. The peptide conjugate was also effective in redn. of incidence of type II collagen-induced arthritis in mice.

L6 ANSWER 190 OF 224 BI

ANSWER 167 OF 224 CAPLUS COPYRIGHT 2002 ACS

AN 1991:514176 CAPLUS

DN 115:114176

TI Preparation of O-[[(phenylcyanoalkyl) amino] alkyl] benzene derivatives as immunosuppressants

IN Liang, Chi Dean; McKearn, John P.; Farah, John M., Jr.; Mueller, Richard A.

PA Searle, G. D., and Co., USA

SO Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 434095	A1	19910626	EP 1990-125245	19901221
	EP 434095	B1	19940202		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5162569	A	19921110	US 1990-623596	19901212
	CA 2032827	AA	19910622	CA 1990-2032827	19901220
	JP 04210667	A2	19920731	JP 1990-419049	19901221
	AT 101125	E	19940215	AT 1990-125245	19901221
	ES 2062286	T3	19941216	ES 1990-125245	19901221
	US 5486539	A	19960123	US 1994-204121	19940301
	US 2001016602	A1	20010823	US 2001-766722	20010122
	US 6451852	B2	20020917		
PRAI	US 1989-456004	A	19891221		
	US 1990-609145	A	19901106		
	US 1990-623596	A	19901212		
	EP 1990-125245	A	19901221		
	US 1992-926732	B1	19920806		
	US 1994-204121	A3	19940301		
	US 1996-589131	B1	19960122		
	US 1997-851762	B1	19970506		
	US 1998-76698	B1	19980512		
	US 1999-237187	B1	19990125		
	US 2000-499555	B1	20000207		

OS MARPAT 115:114176

AB The title compds. [I; m = 1, 2; n = 1-5; R1 = H, (hydroxy)alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, alkenyl, alkynyl; R6 = alkyl; R8-R10, R12-R16 = H, OH, (hydroxy)alkyl, alkoxy, alkenyl, alkynyl, alkylcarbonyl, alkoxy carbonyl, alkylcarbonylalkenyl, alkylaminocarbonyl, alkoxyalkyl; provided that at least one R12 and R16 is selected from groups other than H], useful for treatment of autoimmune or inflammatory diseases, are prepd. Thus, 2.6 g Pd(OAc)2 was added to 4.8 g verapamil in benzene and the mixt. was stirred at room temp. for 3 days, flushed with CO, MeOH added, and after 4 h 1.5 equiv Et3N was added to give 2.2 g I (m = 2, n = 3, R1 = Me, R6 = CHMe2, R8 = R12 = R15 = H, R9 = R10 = R13 = R14 = MeO, R16 = CO2Me) which was converted into the citric acid salt (II). II in vitro suppressed Con A-stimulated proliferation of T-cells in spleen cell harvested from female mice with IC50 of 7.1 .mu.M. Approx. 40 I were prepd.

=>

L6 ANSWER 151 OF 224 CAPLUS COPYRIGHT 2002 ACS
 AN 1994:23551 CAPLUS
 DN 120:23551
 TI Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
 IN Andersen, Anders Joergen; Aston, Roger; Carlen, Peter Louis; Doob, Penelope Reed; Macfadden, Douglas Kevin; Phipps, David James; Rathjen, Deborah; Widmer, Fred
 PA Peptide Technology Ltd., Australia; Drug Royalty Corp.
 SO PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9320102	A1	19931014	WO 1993-GB649	19930329
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9338953	A1	19931108	AU 1993-38953	19930329
	AU 684713	B2	19980108		
	ZA 9302233	A	19940929	ZA 1993-2233	19930329
	EP 635027	A1	19950125	EP 1993-907942	19930329
	EP 635027	B1	20000712		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07507061	T2	19950803	JP 1993-517220	19930329
	RU 2130317	C1	19990520	RU 1994-46096	19930329
	EP 960886	A1	19991201	EP 1999-101349	19930329
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 194495	E	20000715	AT 1993-907942	19930329
	ES 2149203	T3	20001101	ES 1993-907942	19930329
	US 5756449	A	19980526	US 1995-302829	19950224
	US 5686417	A	19971111	US 1995-554758	19951108
	AU 9863542	A1	19980618	AU 1998-63542	19980422
	AU 725680	B2	20001019		
	AU 9922549	A1	19990520	AU 1999-22549	19990331
	AU 718442	B2	20000413		
	US 6265374	B1	20010724	US 1999-421845	19991020
PRAI	US 1992-858832	A2	19920327		
	DK 1992-645	A	19920514		
	US 1992-915118	A2	19920717		
	US 1992-987674	A2	19921209		
	EP 1993-907942	A3	19930329		
	WO 1993-GB649	A	19930329		
	US 1994-232360	B1	19940422		
	US 1995-302829	A1	19950224		
	AU 1998-63542	A3	19980422		
	US 1998-82837	A1	19980521		
OS	MARPAT 120:23551				
AB	Peptide T (ASTTTNYT; from HIV glycoprotein gp120, involved in binding to CD4 antigen) and its linear or cyclic analogs and derivs. are useful in the treatment or prevention of inflammation, multiple sclerosis, myelopathies (including HTLV-1 virus-assocd. myelopathy), and symptoms and diseases assocd. with chronic immune activation (e.g. chronic fatigue syndrome, toxic shock, etc.). Peptide T and analogs were used in the treatment of patients with HTLV-1 myelopathy, multiple sclerosis, and arthritis, etc.				

L6 ANSWER 144 OF 224 CAPLUS COPYRIGHT 2002 ACS
AN 1995:377309 CAPLUS
DN 122:123117
TI Prevention and **treatment** of septic **shock** with an
immunosuppressant, especially cyclosporin
IN Chedid, Louis; Bahr, Georges; Lefrancier, Pierre
PA Vacsyn SA, Fr.
SO Fr. Demande, 17 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2706772	A1	19941230	FR 1993-7559	19930622
	FR 2706772	B1	19950901		
AB	Immunosuppressants (e.g. cyclosporin A or FK 506) are used for the prepn. of medicaments for the prevention or treatment of clin. manifestations of septic shock in humans. Efficacy of cyclosporin A was demonstrated with an animal model of endotoxic shock.				

L6 ANSWER 151 OF 224 CAPLUS COPYRIGHT 2002 ACS